Oxycodon Hcl Retard Lannacher

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxycodon Hcl Retard Lannacher (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodon Hcl Retard Lannacher, is an opioid analgesic presented as a controlled‑release oral formulation for systemic use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are insufficient. GNH India supplies Oxycodon Hcl Retard Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Oxycodon Hcl Retard Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodon Hcl Retard is an opioid analgesic that acts within the central nervous system to relieve pain.

Chronic cancer‑related pain: provides sustained relief for patients with persistent tumor‑associated pain.
Post‑operative pain: manages moderate to severe pain following major surgical procedures.
Severe non‑cancer chronic pain: reduces pain intensity in conditions such as severe osteoarthritis or neuropathic pain when other treatments have failed.
Acute severe injury pain: controls intense pain from traumatic injuries requiring strong analgesia.
Palliative care pain: alleviates distressing pain in end‑of‑life care settings.

How It Works

Oxycodone hydrochloride binds primarily to μ‑opioid receptors in the brain and spinal cord, activating inhibitory G‑protein pathways that decrease neuronal excitability and reduce the transmission of nociceptive signals. This receptor activation also modulates descending pain pathways, producing analgesia throughout the central nervous system.

Side Effects

Oxycodon Hcl Retard may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

Constipation: reduced gastrointestinal motility leading to hard stools.
Nausea: feeling of queasiness, often accompanied by vomiting.
Drowsiness: increased sleepiness or fatigue.
Dry mouth: reduced salivary flow causing oral discomfort.
Dizziness: light‑headed sensation, especially on standing.
Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing that can be fatal.
Severe hypotension: marked drop in blood pressure leading to fainting.
Opioid use disorder: dependence or addiction with compulsive use.
Seizures: rare occurrence of convulsive episodes.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Adrenal insufficiency: impaired cortisol production causing fatigue and weakness.

Precautions & Warnings

When prescribing Oxycodon Hcl Retard, clinicians should evaluate patient history and monitor for specific safety concerns.

Assess renal and hepatic function: adjust therapy if impairment is present.
Evaluate for respiratory disorders: avoid in patients with severe COPD or sleep‑apnea.
Screen for substance‑use disorder: consider risk of dependence before initiating therapy.
Use caution in the elderly: increased sensitivity to sedative effects and falls.
Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol.
Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Avoid Interactions

Oxycodon Hcl Retard can interact with several medication classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined CNS depression can cause profound respiratory depression.
Muscle relaxants: additive sedative effects increase risk of overdose.
MAO inhibitors: may precipitate hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., ketoconazole): increase oxycodone plasma levels, requiring dose adjustment.
CYP3A4 inducers (e.g., rifampicin): reduce oxycodone exposure, potentially decreasing analgesia.
Antihistamines: may enhance drowsiness and dizziness.
Antidepressants (SSRIs/SNRIs): can modestly increase serotonergic activity, monitoring for serotonin syndrome.
Diuretics: may potentiate hypotensive effects, especially orthostatic changes.

Frequently Asked Questions

Oxycodon Hcl Retard Lannacher is an oral, controlled‑release formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain, including cancer‑related pain, post‑operative pain, and severe chronic non‑cancer pain when other analgesics are insufficient.

Oxycodone hydrochloride acts as an agonist at μ‑opioid receptors in the central nervous system. By activating these receptors, it inhibits the release of neurotransmitters involved in pain signaling, reduces neuronal excitability, and modulates descending pain pathways, resulting in analgesia.

The appropriate dose of Oxycodon Hcl Retard Lannacher is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition. Dosage adjustments are made individually and should follow local prescribing guidelines.

Oxycodon Hcl Retard is generally contraindicated during pregnancy because opioids can cause fetal dependence, neonatal respiratory depression, and other adverse outcomes. It is also not recommended while breastfeeding, as oxycodone can be excreted in breast milk and may affect the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with immediate‑release opioids, Oxycodon Hcl Retard provides a prolonged analgesic effect, allowing twice‑daily dosing and more stable plasma concentrations. It is often preferred over morphine sulfate for patients needing consistent pain control, though individual response and side‑effect profiles vary.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually with water. Because it is a controlled‑release tablet, it should be swallowed whole and not crushed, chewed, or split, to maintain the intended release profile and avoid dose dumping.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of respiratory compromise and misuse, especially during initiation and dose changes.

Contra‑indications include patients with known hypersensitivity to oxycodone or any formulation component, those with severe respiratory depression, acute or severe asthma, paralytic ileus, and individuals taking MAO‑inhibitors within 14 days. Caution is also advised for the elderly and those with significant hepatic or renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.